{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=5", "query": { "intervention": "Placebo- matched", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 7049, "total_pages": 705, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T12:13:23.688Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07869654", "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Friedreich Ataxia", "Cardiomyopathies", "Central Nervous System Diseases", "Neuromuscular Diseases", "Mitochondrial Diseases", "Mitochondrial Dysfunction", "Genetic Disease" ], "interventions": [ { "name": "ATI-105", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adjuvia Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2026-10-26", "completion_date": "2027-06-27", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07869654" }, { "nct_id": "NCT01044537", "title": "A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04937319", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2010-02", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2017-03-10", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Cypress, California • Miami, Florida", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Cypress", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01044537" }, { "nct_id": "NCT00474175", "title": "Benzocaine Gel Toothache Dose-Response Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Toothache" ], "interventions": [ { "name": "Placebo gel", "type": "DRUG" }, { "name": "benzocaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 577, "start_date": "2007-05", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 8, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 5 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474175" }, { "nct_id": "NCT03777657", "title": "Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric, or Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 997, "start_date": "2018-12-13", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 6, "location_summary": "Sacramento, California • Newnan, Georgia • Columbus, Ohio + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "West Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03777657" }, { "nct_id": "NCT00737594", "title": "Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Portal Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Cobiprostone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sucampo Pharma Americas, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2008-07", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00737594" }, { "nct_id": "NCT01443845", "title": "Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COPD", "COPD Exacerbation", "Lung Diseases", "Respiratory Disorders", "Pulmonary Disease", "Chronic Obstructive Lung Diseases", "Chronic Obstructive Airway Disease" ], "interventions": [ { "name": "Roflumilast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 2354, "start_date": "2011-09-30", "completion_date": "2016-01-31", "has_results": true, "last_update_posted_date": "2017-04-13", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 217, "location_summary": "Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01443845" }, { "nct_id": "NCT03001557", "title": "Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Irregular Sleep-Wake Rhythm Disorder" ], "interventions": [ { "name": "Lemborexant 2.5 mg", "type": "DRUG" }, { "name": "Lemborexant 5 mg", "type": "DRUG" }, { "name": "Lemborexant 10 mg", "type": "DRUG" }, { "name": "Lemborexant 15 mg", "type": "DRUG" }, { "name": "Lemborexant-matched placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "60 Years to 90 Years" }, "enrollment_count": 63, "start_date": "2016-12-20", "completion_date": "2020-04-17", "has_results": true, "last_update_posted_date": "2021-05-17", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 37, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03001557" }, { "nct_id": "NCT05875441", "title": "Efficacy and Safety Study of Moxidectin in Adults With Scabies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Scabies" ], "interventions": [ { "name": "Moxidectin Oral Product", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicines Development for Global Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-11-23", "completion_date": "2025-02-11", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 5, "location_summary": "Los Angeles, California • Miami, Florida • Tampa, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05875441" }, { "nct_id": "NCT01764841", "title": "Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiectasis" ], "interventions": [ { "name": "Ciprofloxacin DPI (BAYQ3939)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2013-05-02", "completion_date": "2016-03-09", "has_results": true, "last_update_posted_date": "2018-01-24", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 39, "location_summary": "Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 34 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764841" }, { "nct_id": "NCT02537002", "title": "Single Dose Study of PF-05230907 in Healthy Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-05230907", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 17, "start_date": "2015-09", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-04-29", "last_synced_at": "2026-11-07T12:13:23.688Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02537002" } ] }